Featured Research

from universities, journals, and other organizations

Mechanism favors rejection in transplantation of porcine cartilage

Date:
November 25, 2013
Source:
IDIBELL-Bellvitge Biomedical Research Institute
Summary:
Researchers have shown that inhibition of one of the basic components of the complement system protects chondrocytes (cartilage cells) from porcine rejection of xenotransplantation (transplantation between animals of different species).

Researchers at the Bellvitge Institute of Biomedical Research (IDIBELL) led by Cristina Costa from the New Therapies on Genes and Transplantation group have shown that inhibition of one of the basic components of the complement system protects chondrocytes (cartilage cells) from porcine rejection of xenotransplantation (transplantation between animals of different species).

Complement system

The complement system is a key component in the process of innate immunity. "This is the first response of the organism to external pathogens," explained Cristina Costa " and in recent years there have been very relevant jobs that establish that the complement system may be an important therapeutic target in diseases of cartilage."

In that vein, the group Cristina Costa works in xenotransplantation research of cartilage cells (chondrocytes) pig in human joints that have suffered a traumatic injury. This particular work shows that one of the components of the complement system effectors: C5 plays a major role in the rejection.

In a first phase the researchers inhibited pharmacologically C5 in an experimental mouse model and injected them with porcine chondrocytes. "We note that there is a protective effect. The animals without C5 present more preserved cartilage tissue and less cellular infiltrate. "

Description of the mechanism

After confirming the protective effect of C5 inhibition, the researchers studied the molecular mechanisms which enable this component of the innate immune response are. The studies were conducted by exposing porcine chondrocytes in human serum " so that the results bring us one step closer to clinical application " noted Costa .

"We found that activation of the human complement system not directly cause cell death of porcine chondrocytes but activates various inflammatory processes, adhesion and secretion of cytokines and chemokines. All related to xenograft rejection. "

Cartilage transplant

Cartilage transplantation between humans is not widely applied in the clinic but has already proved successful in the regeneration of this tissue in traumatic injuries, especially in athletes. Autologous transplants are performed (with cells from the same person) or allogeneic (cells from another person). "In both cases," explains Cristina Costa " the limitation is in the number of cells. If we get that xenotransplantation work we increase the number and quality of cells available for transplantation. "

In the future, according to the researcher, "maybe we could apply the xenotransplantation of porcine chondrocytes patients of osteoarthritis or even rheumatoid arthritis " but has warned Costa "in these cases other inflammatory and immunological processes that hinder the success of transplantation are combined."


Story Source:

The above story is based on materials provided by IDIBELL-Bellvitge Biomedical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. Sommaggio, M. Pιrez-Cruz, J.L. Brokaw, R. Mαρez, C. Costa. Inhibition of complement component C5 protects porcine chondrocytes from xenogeneic rejection. Osteoarthritis and Cartilage, 2013; DOI: 10.1016/j.joca.2013.09.002

Cite This Page:

IDIBELL-Bellvitge Biomedical Research Institute. "Mechanism favors rejection in transplantation of porcine cartilage." ScienceDaily. ScienceDaily, 25 November 2013. <www.sciencedaily.com/releases/2013/11/131125121718.htm>.
IDIBELL-Bellvitge Biomedical Research Institute. (2013, November 25). Mechanism favors rejection in transplantation of porcine cartilage. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/11/131125121718.htm
IDIBELL-Bellvitge Biomedical Research Institute. "Mechanism favors rejection in transplantation of porcine cartilage." ScienceDaily. www.sciencedaily.com/releases/2013/11/131125121718.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins